ERBB2 and breast carcinoma: HER2/ERBB2 is the most widely studied, where protein overexpression or gene amplification defines one of the three primary breast cancer groups and targeting the HER2 protein and/or blocking its kinase function greatly improves overall survival is now standard of care for patients with HER2 + breast tumors.